Human tissue-resident peritoneal macrophages reveal resistance towards oxidative cell stress induced by non-invasive physical plasma
Copyright © 2024 Schultze-Rhonhof, Marzi, Carvajal Berrio, Holl, Braun, Schäfer-Ruoff, Andress, Bachmann, Templin, Brucker, Schenke-Layland and Weiss..
In the context of multimodal treatments for abdominal cancer, including procedures such as cytoreductive surgery and intraperitoneal chemotherapy, recurrence rates remain high, and long-term survival benefits are uncertain due to post-operative complications. Notably, treatment-limiting side effects often arise from an uncontrolled activation of the immune system, particularly peritoneally localized macrophages, leading to massive cytokine secretion and phenotype changes. Exploring alternatives, an increasing number of studies investigated the potential of plasma-activated liquids (PAL) for adjuvant peritoneal cancer treatment, aiming to mitigate side effects, preserve healthy tissue, and reduce cytotoxicity towards non-cancer cells. To assess the non-toxicity of PAL, we isolated primary human macrophages from the peritoneum and subjected them to PAL exposure. Employing an extensive methodological spectrum, including flow cytometry, Raman microspectroscopy, and DigiWest protein analysis, we observed a pronounced resistance of macrophages towards PAL. This resistance was characterized by an upregulation of proliferation and anti-oxidative pathways, countering PAL-derived oxidative stress-induced cell death. The observed cellular effects of PAL treatment on human tissue-resident peritoneal macrophages unveil a potential avenue for PAL-derived immunomodulatory effects within the human peritoneal cavity. Our findings contribute to understanding the intricate interplay between PAL and macrophages, shedding light on the promising prospects for PAL in the adjuvant treatment of peritoneal cancer.
| Errataetall: |
CommentOn: Immunol Cell Biol. 2020 Feb;98(2):114-126. - PMID 31709677 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Frontiers in immunology - 15(2024) vom: 03., Seite 1357340 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Schultze-Rhonhof, Laura [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 21.03.2024 Date Revised 12.04.2024 published: Electronic-eCollection CommentOn: Immunol Cell Biol. 2020 Feb;98(2):114-126. - PMID 31709677 Citation Status MEDLINE |
|---|
| doi: |
10.3389/fimmu.2024.1357340 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369945859 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369945859 | ||
| 003 | DE-627 | ||
| 005 | 20240413232603.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240320s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fimmu.2024.1357340 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1374.xml |
| 035 | |a (DE-627)NLM369945859 | ||
| 035 | |a (NLM)38504975 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Schultze-Rhonhof, Laura |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Human tissue-resident peritoneal macrophages reveal resistance towards oxidative cell stress induced by non-invasive physical plasma |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.03.2024 | ||
| 500 | |a Date Revised 12.04.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a CommentOn: Immunol Cell Biol. 2020 Feb;98(2):114-126. - PMID 31709677 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Schultze-Rhonhof, Marzi, Carvajal Berrio, Holl, Braun, Schäfer-Ruoff, Andress, Bachmann, Templin, Brucker, Schenke-Layland and Weiss. | ||
| 520 | |a In the context of multimodal treatments for abdominal cancer, including procedures such as cytoreductive surgery and intraperitoneal chemotherapy, recurrence rates remain high, and long-term survival benefits are uncertain due to post-operative complications. Notably, treatment-limiting side effects often arise from an uncontrolled activation of the immune system, particularly peritoneally localized macrophages, leading to massive cytokine secretion and phenotype changes. Exploring alternatives, an increasing number of studies investigated the potential of plasma-activated liquids (PAL) for adjuvant peritoneal cancer treatment, aiming to mitigate side effects, preserve healthy tissue, and reduce cytotoxicity towards non-cancer cells. To assess the non-toxicity of PAL, we isolated primary human macrophages from the peritoneum and subjected them to PAL exposure. Employing an extensive methodological spectrum, including flow cytometry, Raman microspectroscopy, and DigiWest protein analysis, we observed a pronounced resistance of macrophages towards PAL. This resistance was characterized by an upregulation of proliferation and anti-oxidative pathways, countering PAL-derived oxidative stress-induced cell death. The observed cellular effects of PAL treatment on human tissue-resident peritoneal macrophages unveil a potential avenue for PAL-derived immunomodulatory effects within the human peritoneal cavity. Our findings contribute to understanding the intricate interplay between PAL and macrophages, shedding light on the promising prospects for PAL in the adjuvant treatment of peritoneal cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Comment | |
| 650 | 4 | |a cold atmospheric plasma (CAP) | |
| 650 | 4 | |a human primary macrophages | |
| 650 | 4 | |a immune response | |
| 650 | 4 | |a non-invasive physical plasma (NIPP) | |
| 650 | 4 | |a peritoneal cancer | |
| 650 | 4 | |a peritoneal cavity | |
| 650 | 4 | |a plasma-activated media (PAM) | |
| 650 | 4 | |a plasma-treated solutions (PTS) | |
| 700 | 1 | |a Marzi, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Carvajal Berrio, Daniel Alejandro |e verfasserin |4 aut | |
| 700 | 1 | |a Holl, Myriam |e verfasserin |4 aut | |
| 700 | 1 | |a Braun, Theresa |e verfasserin |4 aut | |
| 700 | 1 | |a Schäfer-Ruoff, Felix |e verfasserin |4 aut | |
| 700 | 1 | |a Andress, Jürgen |e verfasserin |4 aut | |
| 700 | 1 | |a Bachmann, Cornelia |e verfasserin |4 aut | |
| 700 | 1 | |a Templin, Markus |e verfasserin |4 aut | |
| 700 | 1 | |a Brucker, Sara Y |e verfasserin |4 aut | |
| 700 | 1 | |a Schenke-Layland, Katja |e verfasserin |4 aut | |
| 700 | 1 | |a Weiss, Martin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in immunology |d 2010 |g 15(2024) vom: 03., Seite 1357340 |w (DE-627)NLM215811453 |x 1664-3224 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2024 |g day:03 |g pages:1357340 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fimmu.2024.1357340 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2024 |b 03 |h 1357340 | ||